← All companies

VRXA

Veraxa Biotech AG

VRXA Nasdaq Pharmaceutical Preparations EDGAR ↗

$1.83

-0.13 -6.63%

Key statistics

from XBRL data in SEC filings

Market cap

—

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

—

Total assets

—

Gross margin

—

52-week range

$1.70 – $27.36

Recent SEC filings

38 most recent

Annual, quarterly & current reports

6-K Jul 31, 2026 6-K Jul 27, 2026 6-K Jul 27, 2026 6-K Jun 18, 2026 20-F Jun 16, 2026 6-K Jun 11, 2026

Other filings

F-1 Jul 31, 2026 F-1 Jul 31, 2026 SCHEDULE 13D Jun 16, 2026 SCHEDULE 13D Jun 16, 2026 SCHEDULE 13D Jun 15, 2026 SCHEDULE 13D Jun 15, 2026 CERT Jun 10, 2026 8-A12B/A Jun 10, 2026 3 PRIMARY DOCUMENT Jun 10, 2026 3 PRIMARY DOCUMENT Jun 10, 2026 3 PRIMARY DOCUMENT Jun 9, 2026 3 PRIMARY DOCUMENT Jun 9, 2026 3 PRIMARY DOCUMENT Jun 9, 2026 3 PRIMARY DOCUMENT Jun 9, 2026 3 PRIMARY DOCUMENT Jun 9, 2026 8-A12B Jun 9, 2026 424B3 Feb 19, 2026 EFFECT Feb 17, 2026 CORRESP Feb 13, 2026 F-4/A Feb 13, 2026 CORRESP Feb 12, 2026 UPLOAD Feb 11, 2026 F-4/A Feb 3, 2026 CORRESP Nov 28, 2025 F-4/A Nov 28, 2025 UPLOAD Nov 20, 2025 425 Sep 30, 2025 F-4/A Sep 29, 2025 CORRESP Sep 29, 2025 UPLOAD Aug 27, 2025 F-4/A Jul 31, 2025 F-4 Jul 31, 2025